Royalty Report: Drugs, Antibody, Cancer – Collection: 135993

$150.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 8

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 8

Primary Industries

  • Drugs
  • Antibody
  • Cancer
  • Drug Discovery
  • Immune
  • Disease
  • Dermatology
  • DNA

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 135993

License Grant
Licensor of the Netherlands entered into a Collaboration and License Agreement and Share Subscription Agreement with the Licensee.  Under the terms of the Collaboration Agreement, the parties have agreed to collaborate with respect to the research, discovery and development of bispecific antibodies utilizing the Licensor’s proprietary bispecific technology platform. The collaboration encompasses up to 11 independent programs, including two of the Licensor’s current preclinical immuno-oncology discovery programs. For one of the current preclinical programs, Program 1, the Licensor retains the exclusive right to develop and commercialize products and product candidates in the United States, while Licensee has the exclusive right to develop and commercialize products and product candidates arising from such program outside the United States.  The Licensor has the option to co-fund development of products arising from two other programs in exchange for a share of profits in the United States, as well as the right to participate in a specified proportion of detailing activities in the United States for one of such programs. Should Program 1 fail to successfully complete IND-enabling toxicology studies, the Licensor would be granted an additional option to co-fund development of a program in exchange for a share of profits in the United States.  The Licensor retains the rights to its bispecific technology platform as well as clinical and pre-clinical candidates and future programs emerging from the Company’s platform that are outside the scope of the Collaboration Agreement.
License Property
The collaboration encompasses up to 11 independent programs, including two of the Licensor’s current preclinical immuno-oncology discovery programs, with respect to the research, discovery and development of bispecific antibodies utilizing the Licensor’s proprietary bispecific technology platform.
A bispecific monoclonal antibody (BsMAb, BsAb) is an artificial protein that can simultaneously bind to two different types of antigen.
Field of Use
This agreement applies to the drug development industry.

IPSCIO Record ID: 296181

License Grant
The Parties have a collaboration and exclusive license agreement.  Under the terms of the amended agreement, Licensor granted an exclusive, sub-licensable worldwide license to research, develop, manufacture, market and sell products based on our proprietary technology.
The November amendment adds an additional dual-reactive antibody product candidate.
License Property
Licensor granted exclusive rights to three monospecific antibody product candidates targeting TIM-3 (TSR-022), LAG-3 (TSR-033) and PD-1 (TSR-042) and a bispecific antibody product candidates targeting PD-1 and LAG-3.

The AnaptysBio platform offers unmatched capabilities in antibody discovery, generation and optimization, and we are excited about the potential for these programs. We look forward to working with the AnaptysBio team to develop novel immuno-oncology-based approaches to a variety of tumors.

Field of Use
The field of use is for the discovery, generation and optimization of certain specified immunotherapy antibodies.  With the amendment, the field is for performing initial discovery and development of therapeutic antibodies with the goal of generating immunotherapy antibodies for use in the treatment of cancer.

IPSCIO Record ID: 250946

License Grant
The Parties will collaborate on the discovery of monospecific antibodies to develop bispecific therapeutics targeting cytokine-receptor pathways using the Canadian Licensors antibody discovery capabilities and its proprietary AzymetricTM and EFECTTM platforms.  The Danish Licensee will have exclusive rights to develop and commercialize two bispecific antibody candidates for application in dermatology indications and the Canadian Licensor will retain the rights to develop antibodies targeting cytokine-receptor pathways in any non-dermatology indications.
License Property
The Danish Licensee granted the Canadian Licensor a non-exclusive, worldwide, royalty-free research and development license allowing the Licensee to perform certain research and development activities and a non-exclusive license to use certain intellectual property to develop and commercialize antibodies targeting cytokine-receptor pathways in any non-dermatology indications.
Field of Use
The Danish Licensee will commercialize the Antibodies for dermatology applications.

IPSCIO Record ID: 258622

License Grant
The Swedish Licensee gained access to the full OmniAb® transgenic animal technology platform, including OmniRat®, OmniMouse®, OmniFlic® and OmniChickenâ„¢, for its drug discovery efforts.  The Licensee is an immuno-oncology biotech.
License Property
The antibody discovery technology is a platform to offer access to three species that produce fully-human antibodies.

IPSCIO Record ID: 101938

License Grant
A wholly-owned subsidiary of the parent company entered into a Collaboration, License and Option Agreement with Licensee to discover, develop and commercialize small molecule antagonists for immuno-oncology and precision oncology targets.
License Property
Under the Collaboration Agreement, Licensor has the responsibility for conducting all discovery and preclinical activities, including Investigational New Drug (IND) enabling studies and providing Phase 1 clinical trial supply, and Licensee is responsible for all clinical development, regulatory and commercialization efforts worldwide, excluding India and Russia. The Collaboration Agreement provides that the parties will collaborate exclusively in immuno-oncology for an initial period of approximately two years, with the option for Licensee to extend the broad immuno-oncology exclusivity.
Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 284944

License Grant
The Company granted a non-exclusive license to Licensee to develop and commercialize certain drug candidates under the Licensor patents and know-how.
License Property
Licensor has a long history of discovering and developing innovative therapeutic candidates derived from its unique platform of antibody technologies.  Licensor built a pipeline of fully-funded programs discovered by its licensees and partners from direct use of the Company’s proprietary antibody discovery platform and from product candidates it discovered and advanced prior to licensing them to licensees who assumed the responsibilities of subsequent development, regulatory approval and commercialization.
Field of Use
Many of these licenses are the result of Company’s pioneering efforts in the discovery and development of antibody therapeutics.

IPSCIO Record ID: 190836

License Grant
The Licensor granted the Licensee a worldwide, royalty-bearing antibody sequence pair-specific exclusive license to research, develop and commercialize certain licensed products.
License Property
Under the agreement, Licensor is sharing certain research and development responsibilities with Licensee to generate bispecific antibodies with the Azymetric platform.
Field of Use
After the research program term, Licensee will be solely responsible for the further research, development, manufacturing and commercialization of the products.

IPSCIO Record ID: 289177

License Grant
With this agreement, Licensee wishes Licensor to apply its technology and know-how to genetically engineer a Single-Chain Antibody.

The Licensor of Scotland agrees to grant the German Licensee under the patent rights a non-exclusive world-wide licence to the extent necessary to commercialise the Deimmunised antibody and/or the deliverables in the field.

Licensor grants for each specific Deimmunised antibody a non-exclusive licence under the patent rights to the extent necessary for worldwide commercialisation of the Deimmunised antibody derived from the specific Single-Chain Antibody sequence.

License Property
Licensor has certain proprietary technology, materials and know-how in genetic engineering of biological materials, including single-chain antibodies, relating to removal of potentially immunogenic sequences, from the variable regions of antibodies, or Delmmunisation to produce an antibody for therapeutic and/or in vivo diagnostic purposes.

Licensee is the owner of a cDNA which encodes a Single-Chain Antibody which binds to a specific antigen.

Licensor patent rights shall mean all patent applications and granted patents relevant to Deimmunization Technology.

Deimmunised antibody shall mean all genetically engineered variant(s) of the single-chain antibody  arising from the research.

Deimmunization technology shall mean the technical process applied by Licensor to generate Deimmunised antibody as outlined in the research program.

DeImmunisation increases the clinical potential of antibody and protein therapeutics by eliminating/reducing the T-cell response caused when the therapeutic molecule is recognised as foreign by the patient's immune system. The technology is based on ‘peptide threading' and works by identifying potential T-cell epitopes on the therapeutic antibody or protein. T-cell epitopes are sites on the therapeutic molecule which can bind to MHC class II, triggering a T-cell mediated immune response. Once this potentially immunogenic region of the antibody is identified, it is removed from the molecule by single amino acid substitutions, thus eliminating/reducing the therapeutic antibody or protein's immunogenicity and increasing its safety. This can be done without compromise to efficacy.

Field of Use
The field shall mean the field of human therapy and human in vivo and in vitro diagnostics limited to the Single-Chain Antibody.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.